WHAT IS CLAIMED IS:

1. A inhibitor of protein modification products formation comprising a 5-substituted tetrazole ring compound having a methylene-containing group at the 1- or 3-position of the terazole ring in free or salt form as an active ingredient.

2. The inhibitor of protein modification products formation according to claim 1, wherein the compound as the active ingredient is selected from compounds of formula (I);



(I)

[wherein R1 and R2 represent each the same or different monovalent organic group] in free or salt form.

3. The inhibitor of protein modification products formation according to clam 1, wherein the compound as the active ingredient is selected from compounds of formula (II);



(II)

[wherein R1 and R2 represent each the same or different monovalent organic group] in free or salt form.

4. The inhibitor of protein modification products formation according to clam 2 or 3, wherein R1 is an optionally substituted phenyl group and R2 is an optionally substituted heterocyclic group of not more than 10 ring atoms.

5. The inhibitor of protein modification products formation according to clam 2 or 3, wherein R1 is an optionally substituted phenyl group and R2 is a lower alkyl group, a lower alkoxy group or a hydroxy group.

6. The inhibitor of protein modification products formation according to clam 2 or 3, wherein R1 is substituted or unsaturated phenyl group and R2 is morpholino group.

7. The inhibitor of protein modification products formation according to clam 2 or 3, wherein R1 is a

substituted or unsubstituted phenyl group and R2 is a 5-methyl-3a,6a-dihydro-1H-pyrrolo[1,2,3]triazole-4,6-dione group.

8. The inhibitor of protein modification products formation according to clam 2 or 3, wherein R1 is a substituted or unsubstituted phenyl group and R2 is a hydroxymethyl group.

9. The inhibitor of protein modification products formation according to any one of claims 1 to 8, wherein the protein modification products is selected from AGEs, ALEs and combinations thereof.

10. The inhibitor of protein modification products formation according to claim 9, wherein the protein modification products is AGE.

11. The inhibitor of protein modification products formation according to claim 10, wherein AGE is pentosidine.

12. A renal tissue protecting agent comprising the inhibitor of protein modification products formation according to any one of claims 1 to 8.

13. A peritoneal dialysate comprising the inhibitor of protein modification products formation according to any one of claims 1 to 8.

14. A hemodialysis fluid comprising the inhibitor of protein modification products formation according to any one of claims 1 to 8.

15. A method for reducing the amount of carbonyl compounds in a liquid sample, which comprises contacting said liquid sample with the inhibitor of protein modification products formation according to any one of claims 1 to 8.

16. A method for suppressing the formation of protein modification products in the blood or peritoneal dialysate of a patient, which comprises contacting said blood or peritoneal dialysate with the inhibitor of protein modification products formation according to any one of claims 1 to 8.

17. A method for treating a disease mediated by the formation of protein modification products, which comprises administrating a therapeutically effective amount of the inhibitor of protein modification products formation

according to any one of claims 1 to 8 to a patient in need of such treatment.

18 Use of the inhibitor of protein modification products formation according to any one of claims 1 to 8 for preparation of a medicament for treating a disease mediated by the formation of protein modification products.